Vetter Serializes the First Product for South Korea
![](/46/pdcnewsitem/03/44/29/cZeF1z0KrzLYukI.jpg)
Vetter has announced the manufacture of the first commercial batches with single-use identification numbers. Following the introduction of a comprehensive serialization service last year, the company has now implemented product serialization for secondary packaging for one of the world's leading pharmaceutical companies. In accordance with the requirements from the South Korean Ministry of Food and Drug Safety (MFDS) Vetter's solution identifies the drugs on the folding boxes via a 2D data matrix code with a serial number, GTIN, expiry date and batch number.
As the number of counterfeit drugs continues to grow, regulatory authorities around the world are increasingly relying on clear identification of products through serialization. They are demanding that the smallest packaging unit be marked with a single-use identification number. South Korea is among those countries requiring serialization with an aim towards protecting against counterfeiting, as well as a more secure supply chain.
"Together with our customer, we prepared for these requirements very early on," says Thomas Otto, managing director at Vetter. "We have been active in filling and final packaging for the company for years. Thanks to our serialization service, our partner can now meet the regulatory requirements for South Korea. We are, however, also aware of the fact that regulatory requirements differ from one country to the next. Therefore, we offer pharma and biotech companies a wide range of options that will give them flexibility when reacting to different regulatory standards."
Presently, South Korea has only asked for serialization on the folding package. China, however, has legislated use of 1D linear codes including aggregation with the shipping box. As such, Vetter provides a broad variety of services in secondary packaging, primary packaging and final assembly that give its customers a great deal of flexibility to accommodate various regulatory or market needs. The company's comprehensive serialization service includes a range of formats for serial numbers, different code systems; such as a 2D data matrix codes, interfaces and reports, as well as various aggregation depths.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance